Skip to main content
Premium Trial:

Request an Annual Quote

Yourgene Inks Deal With EKF Diagnostics to Offer NIPT, Other Genomic Tests in US

NEW YORK — UK molecular diagnostics firm Yourgene said on Tuesday that it has partnered with EKF Diagnostics to offer noninvasive prenatal and other genomic testing services in the US.

Under the terms of the five-year deal, Yourgene will provide EKF subsidiary Advanced Diagnostics Laboratory with proprietary reagents and next-generation sequencing analysis software to enable the Texas-based CLIA lab to build a noninvasive prenatal testing service that can provide results within 48 hours. ADL will also offer certain of Yourgene's PCR tests for cystic fibrosis, aneuploidy, and DPYD deficiency in chemotherapy toxicity.

Financial and other terms of the agreement were not disclosed.

"ADL Health [is] a well-established group in the US with a large clinical network of customers positioned to increase uptake of the tests," Yourgene CEO Lyn Rees said in a statement. "This partnership is testament to the strength of our technical capabilities and accelerates our US growth plans to broaden our portfolio in the region with strategic partners."

In October, Yourgene reported more than doubling its revenues for the first half of its fiscal year 2022 due to growing demand for its genomic services.